Aculys Pharma is a clinical-stage biopharmaceutical company dedicated to addressing significant unmet medical needs in the field of neurology, particularly in Japan. The company focuses on developing innovative treatments for complex neuroscience diseases by leveraging drugs that have already received approval in other countries. This approach aims to mitigate the "drug lag" phenomenon in Japan, where new pharmaceuticals often take longer to be approved compared to their counterparts in the EU and the US. Aculys is actively working to enhance patient access to these therapies, thereby improving the quality of life for patients and their families affected by neurological conditions.

The company is currently advancing a pipeline of drug candidates, including pitolisant for narcolepsy and a diazepam nasal spray for the treatment of epileptic seizures. These products are in various stages of clinical trials and regulatory submissions, reflecting Aculys's commitment to accelerating the delivery of effective treatments to the Japanese market. By focusing on the unique challenges posed by Japan's regulatory landscape, Aculys Pharma aims to bridge the gap in treatment availability and address the broader social issues associated with neurological diseases, ultimately striving to improve patient outcomes and reduce the stigma surrounding these conditions.

Japan

Aculys - Beyond the development and commercialization of new medicines, Aculys is committed to the patient experience including the awareness, screening, diagnosis, treatment of disease and the resolution of surrounding social issues for patients and their families confronted with neurological and psychiatric disease. The company looks to form comprehensive solutions through cross-sectional partnerships using new technologies to enhance the patient experience.

Aculys Pharma

Company Details